The market of traditional Chinese medicine formula granules is expected to exceed 150 billion, and many pharmaceutical companies are accelerating their deployment

Compared with traditional decoction pieces, traditional Chinese medicine formula granules have the advantages of convenience in taking and carrying, and are more in line with the fast-paced life of modern people
.
Guorong Securities pointed out that it is conservatively estimated that the replacement rate of formula particles in China in the future is about 50%, and the corresponding market size is expected to exceed 150 billion
.
From November 1, 2021, the more than 20 years of pilot work of traditional Chinese medicine formula granules will officially end, and all qualified traditional Chinese medicine enterprises can produce traditional Chinese medicine formula granules only by filing
.
Subsequently, Jiangsu, Guizhou, Sichuan, Yunnan, Guangdong, Anhui and other places successively issued working procedures and application data requirements for the formulation of quality standards for traditional Chinese medicine formula granules
.
At the same time, the "Notice on Regulating the Clinical Use of Traditional Chinese Medicine Formula Granules in Medical Institutions" jointly issued by the two departments clarifies that the sales sites of traditional Chinese medicine formula granules should be medical institutions that can provide traditional Chinese medicine services after approval or filing, and medical institutions should establish traditional Chinese medicine Formula granule prescription review system, which will be conducive to the standardized and rational application of traditional Chinese medicine formula granules, and help the healthy development of the industry
.
With the release of the New Deal, the 100 billion Chinese medicine formula granule market is attracting many pharmaceutical companies to deploy
.
On February 8, Jilin Aodong issued an announcement saying that Yanbian Pharmaceutical, a holding subsidiary, has received 8 national standard "Chinese Medicine Formula Granules Listing Recording Certificates", including Angelica Formula Granules, Jiu Danshen Formula Granules,
etc.
As of the announcement date, Jilin Aodong has obtained a total of 99 "Recording Certificates for the Listing of Traditional Chinese Medicine Formula Granules".
The company stated that these filing certificates are of great significance to the company's expansion of the traditional Chinese medicine formula granules business, creating favorable conditions for the company's sustainable development and further strengthening the company's core competitiveness
.
At present, in addition to Jilin Aodong and early-stage giants, there are also Xiangxue Pharmaceuticals, Essence Pharmaceuticals, Taiji Group, Jiuzhoutong, Yiling Pharmaceuticals, Panlong Pharmaceuticals, Kunyao Group, Tasly, Xintian Pharmaceuticals, More than 30 listed pharmaceutical companies, including Foci Pharmaceutical, Yibai Pharmaceutical, Zhenbaodao, and Yan'an Bikang, have deployed the Chinese medicine formula granule market
.
According to data from the Ministry of Industry and Information Technology, the market size of traditional Chinese medicine formula granules in 2019 is about 50.
3 billion yuan, and in 2020, it is about 53.
3 billion yuan
.
The agency predicts that the traditional Chinese medicine formula granule industry will maintain rapid growth in the next few years, and the industry scale is expected to reach 100 billion yuan
.
With the completion of the pilot work and the favorable blessing of the new policy, it is expected that more companies will enter the field of traditional Chinese medicine formula granules
.
According to the data, there are nearly 80 enterprises that have obtained the pilot qualification of traditional Chinese medicine formula granules
.
The industry predicts that the market competition may be more intense in the future
.
It is worth mentioning that the traditional Chinese medicine formula granule industry will also face strict challenges
.
For example, quality regulation will be more stringent
.
It is reported that in order to ensure the quality of traditional Chinese medicine formula granules, the State Food and Drug Administration has set up a special office for traditional Chinese medicine formula granules in the State Pharmacopoeia Commission, organized the State Pharmacopoeia Committee to formulate the "Technical Requirements for Quality Control and Standard Formulation of Traditional Chinese Medicine Formula Granules", and started to carry out standard unification, experts Audit work
.
In addition, according to relevant regulations, manufacturers of traditional Chinese medicine formula granules should have complete production capacity such as processing, extraction, concentration, drying, and granulation of decoction pieces, formulate detailed production processes and standard operating procedures for each variety, and strictly implement drug production quality management.
Regulations (GMP) in the relevant provisions
.
This also puts a test on the production capacity and management capacity of the enterprise
.